The pharmaceutical company Solopharm (Grotex LLC) announces a change in leadership. As of July 25, 2025, Mamuka Mikhelashvili has been appointed to the position of Chief Executive Officer (CEO). He previously served as the company's Commercial Director and later as its Executive Director.
Mamuka Mikhelashvili began his career as a pharmacist in a pharmacy chain and now possesses significant management experience in pharmaceutical retail and distribution. He is deeply involved in the strategic development of Solopharm. His appointment as CEO reflects management continuity and is aimed at further strengthening the company's market positions in Russia and on international markets, as well as enhancing operational efficiency.
«Solopharm is a company of high standards, innovative solutions, and dynamic growth. My task is to ensure the development of new business areas and the efficiency of all processes, as well as to maintain our focus on the quality and accessibility of our products», noted Mamuka Mikhelashvili.
The company's founder, Oleg Zherebtsov, in his role as Chairman of the Board of Directors, will continue to define the company's strategy, lead the creation of new production facilities and business lines, and develop Solopharm's biotechnology division.
Solopharm remains committed to its course of developing the pharmaceutical industry in Russia and continues to be a reliable partner for patients, doctors, and the professional community.
Media Contacts: press@grotexmed.com
Solopharm Press Service